Insiders who reported open-market trades in the last 12 months at the companies Jeremy Bender files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jeremy Bender is a corporate insider, tracked as Director of Bicara Therapeutics Inc. (BCAX). InsiderAlpha holds 12 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Jeremy Bender submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Jeremy Bender been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($569K) across all tracked filings.
Jeremy Bender is Director of Bicara Therapeutics Inc. (BCAX). 12 SEC Form 4 filings on record going back to 2024, most recently on 29 July 2026. Most recent open-market trade: sold $179K of DAWN on 18 February 2026. Lifetime open-market sales: $569K.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Jeremy Bender.
InsiderAlpha's records for Jeremy Bender go back to 2024: 12 primary Form 4 filings, an average of 4.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
